Drug Search Results
More Filters [+]

Lusutrombopag

Alternative Names: lusutrombopag, s-888711, mulpleta
Latest Update: 2024-07-22
Latest Update Note: Clinical Trial Update

Product Description

Lusutrombopag is used to treat thrombocytopenia (low platelets in the blood) in adults with chronic liver disease who are scheduled to have a medical or dental procedure. It works by stimulating the bone marrow to produce more platelets. (Sourced from: https://www.mayoclinic.org/drugs-supplements/lusutrombopag-oral-route/description/drg-20443925)

Mechanisms of Action: TPO Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Austria | Belgium | Croatia | Czech | Estonia | European Medicines Agency | Finland | Germany | Hungary | Iceland | Ireland | Italy | Japan | Latvia | Lithuania | Netherlands | Poland | Portugal | Slovakia | Spain | Sweden | United Kingdom | United States

Approved Indications: Thrombocytopenia

Known Adverse Events: Headache

Company: Shionogi
Company Location: OSAKA M0 541-0045
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Lusutrombopag

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Anemia, Aplastic

Phase 3: Thrombocytopenia

Phase 2: Thrombocytopenia|Purpura, Thrombocytopenic, Idiopathic

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

LNA-2024

P4

Not yet recruiting

Anemia, Aplastic

2025-06-01

ChiCTR2400084012

N/A

Not yet recruiting

Anemia, Aplastic

2025-04-30

A pilot study to evaluate the efficacy and safety of lusutrombopag in ITP patients

N/A

Not yet recruiting

Thrombocytopenia|Purpura, Thrombocytopenic, Idiopathic

2024-11-30

IIT2023078

P2

Recruiting

Thrombocytopenia|Purpura, Thrombocytopenic, Idiopathic

2024-09-30

Recent News Events